VARDENAFIL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H32N6O4S
Molecular Weight	488.603
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCC1=NC(C)=C2N1NC(=NC2=O)C3=CC(=CC=C3OCC)S(=O)(=O)N4CCN(CC)CC4

InChI

InChIKey=SECKRCOLJRRGGV-UHFFFAOYSA-N

InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)

HIDE SMILES / InChI

Molecular Formula	C23H32N6O4S
Molecular Weight	488.603
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB00862
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021400s017lbl.pdf

Vardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 5A 30 Target ID: CHEMBL1827 Sources: http://www.drugbank.ca/drugs/DB00862	Inhibitor 8297		1.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Erectile dysfunction 35 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021400s017lbl.pdf	Primary		Approved 8429	Levitra Approved Use LEVITRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction. Launch Date 2003

C_max

Value	Dose	Co-administered	Analyte	Population
30.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27318021	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		VARDENAFIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
22.83 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27318021	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		VARDENAFIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.21 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27318021	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		VARDENAFIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
2.4 mg 12 times / day multiple, respiratory (starting) Highest studied dose Dose: 2.4 mg, 12 times / day Route: respiratory Route: multiple Dose: 2.4 mg, 12 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33325799	healthy, 27.5 years (range: 24-31 years) n = 8 Health Status: healthy Age Group: 27.5 years (range: 24-31 years) Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/33325799	Sources: https://pubmed.ncbi.nlm.nih.gov/33325799
120 mg single, oral Highest studied dose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf	healthy, adult n = 8 Health Status: healthy Age Group: adult Sex: M Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf	Other AEs: Back pain, Myalgia... Other AEs: Back pain Myalgia Abnormal vision Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf
2.4 mg single, respiratory Highest studied dose Dose: 2.4 mg Route: respiratory Route: single Dose: 2.4 mg Sources: https://pubmed.ncbi.nlm.nih.gov/33325799	healthy, adult n = 6 Health Status: healthy Age Group: adult Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/33325799	Sources: https://pubmed.ncbi.nlm.nih.gov/33325799
10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	Disc. AE: Headache, Flushing... AEs leading to discontinuation/dose reduction: Headache (19 patients) Flushing (10 patients) Rhinitis (5 patients) Tachycardia (4 patients) Nausea (5 patients) Liver function test abnormal (4 patients) Dizziness (3 patients) Hypesthesia (3 patients) Abdominal pain (3 patients) Palpitations (3 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34

AEs

AE	Significance	Dose	Population
Abnormal vision		120 mg single, oral Highest studied dose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf	healthy, adult n = 8 Health Status: healthy Age Group: adult Sex: M Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf
Back pain		120 mg single, oral Highest studied dose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf	healthy, adult n = 8 Health Status: healthy Age Group: adult Sex: M Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf
Myalgia		120 mg single, oral Highest studied dose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf	healthy, adult n = 8 Health Status: healthy Age Group: adult Sex: M Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf
Flushing	10 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Headache	19 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Abdominal pain	3 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Dizziness	3 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Hypesthesia	3 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Palpitations	3 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Liver function test abnormal	4 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Tachycardia	4 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Nausea	5 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Rhinitis	5 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	substrate 1037 inhibitor 1767	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2C8 911 CYP2C19 1478	CYP3A5 395 CYP2C8 693 CYP2C19 991 P-gp 1537 BCRP 561 MRP2 205

Drug as perpetrator

Target	Modality	Activity	Metabolite
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	weak [Ki 126 uM]
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	weak [Ki 67.5 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	weak [Ki 73.2 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	yes [Ki 1.4 uM]	M-1 6
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	yes [Ki 20.6 uM]	M-4 4
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	yes [Ki 45 uM]	M-1 6
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	yes [Ki 45 uM]	M-1 6
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	yes [Ki 9.8 uM]	M-1 6

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	major	yes (co-administration study) Comment: label: coadministration with ketoconazole (inhibitor) increased mean AUC and Cmax of vardenafil by 10-fold and 4-fold, respectively; coadministration with erythromycin (CYP3A4 substrate) increased mean AUC and Cmax of vardenafil, respectively; coadministration with indinavir (CYP3A4 inhibitor) increased mean AUC and Cmax of vardenafil by 16 fold and 7 fold, respectively; Ritonavir co-administered with vardenafil resulted in a 49-fold increase in vardenafil AUC and a 13 fold increase in vardenafil Cmax; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	minor
CYP2C8 693	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	minor
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	minor
CYP3A5 395	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	minor
BCRP 561	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/22775210/ Page: 7.0	yes
MRP2 205	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/22775210/ Page: 7.0	yes
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/22775210/ Page: 7.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=17 Page: 17.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:46295	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:46295
MolPort	MolPort-002-672-272	https://www.molport.com/shop/molecule-link/MolPort-002-672-272
ZINC	ZINC000018324776	http://zinc15.docking.org/substances/ZINC000018324776
eMolecules	30390394	https://www.emolecules.com/cgi-bin/more?vid=30390394
eMolecules	36366753	https://www.emolecules.com/cgi-bin/more?vid=36366753
eMolecules	36516854	https://www.emolecules.com/cgi-bin/more?vid=36516854

PubMed

Title	Date	PubMed
The oral efficacy of vardenafil hydrochloride for inducing penile erection in a conscious rabbit model.	2001 Apr	11257708
The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial.	2001 Aug	11494074
Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study.	2001 Feb	11289568
Oral drug therapy for erectile dysfunction.	2001 May	11402584
Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat.	2002	12127092
[Erectile dysfunction. New therapy options ante portas].	2002 Feb 14	11887735
Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial.	2002 Nov-Dec	12399521
Vardenafil: a review of its use in erectile dysfunction.	2003	14636086
[How effective are PDE-5 inhibitors?].	2003 Apr	12715127
Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial.	2003 Apr	12657355
The phosphodiesterase inhibitor 'war'.	2003 Apr	12656917
US advertising campaign begins for alternative to sildenafil.	2003 Aug 30	12946961
Pro-erectile effect of vardenafil: in vitro experiments in rabbits and in vivo comparison with sildenafil in rats.	2003 Dec	14644128
Vardenafil: a new approach to the treatment of erectile dysfunction.	2003 Dec	14622502
Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists.	2003 Dec	14622499
Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells.	2003 Jan 1	12393651
New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.	2003 Jun	12852189
[Conservative treatment of erectile dysfunction].	2003 Jun 1	12847815
Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003.	2003 Jun 17	12814989
[New PDE-5 inhibitor for treatment of impotence. 9 out of 10 have erections again].	2003 Jun 26	12916343
Gateways to clinical trials. March 2003.	2003 Mar	12731460
Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study.	2003 Mar	12610037
Gateways to clinical trials.	2003 May	12808477
Effects of medical or surgical castration on erectile function in an animal model.	2003 May-Jun	12721214
Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference.	2003 Nov	14693300
Overview of phosphodiesterase 5 inhibition in erectile dysfunction.	2003 Nov 6	14609619
[Drug therapy of erectile dysfunction--the current status].	2003 Oct	14569380
Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey.	2003 Oct	14551572
New drugs and dosage forms.	2003 Oct 1	14531237
Novel PDE5 inhibitors for the treatment of male erectile dysfunction.	2003 Oct-Nov	14656408
[Medication of the month. Vardenafil (Levitra)].	2003 Sep	14626653
FDA approves new drug for treatment of erectile dysfunction in men.	2003 Sep-Oct	14666896
Spotlight on vardenafil in erectile dysfunction.	2004	14960129
Tadalafil and vardenafil.	2004 Apr	15124623
Role of the cardiologist: clinical aspects of managing erectile dysfunction.	2004 Apr	15115189
Drug approval highlights for 2003.	2004 Feb	14872168
[Treatment of erectile dysfunction].	2004 Feb 29	15077482
The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men.	2004 May	15082207

Patents

Sample Use Guides

In Vivo Use Guide

For most patients, the starting dose is 10 mg, up to once daily. Increase to 20 mg or decrease to 5 mg based on efficacy/tolerability. A starting dose of 5 mg LEVITRA should be considered in patients ≥ 65 years of age. LEVITRA is taken orally, approximately 60 minutes before sexual activity. The maximum recommended dosing frequency is one tablet per day.

Route of Administration: Oral

In Vitro Use Guide

Treatment with vardenafil at concentrations of 50, 100, and 250 umol/L increased expression of PlGF in a dose-dependent manner in human umbilical vein endothelial cells.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:44:26 GMT 2023` Edited by `admin` on `Fri Dec 15 15:44:26 GMT 2023`
Record UNII	UCE6F4125H
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VARDENAFIL

Official Name

English

VARDENAFIL [USAN]

Common Name

English

VARDENAFIL [EMA EPAR]

Common Name

English

VARDENAFIL [VANDF]

Common Name

English

VARDENAFIL [HSDB]

Common Name

English

vardenafil [INN]

Common Name

English

Vardenafil [WHO-DD]

Common Name

English

VARDENAFIL [MART.]

Common Name

English

1-((3-(3,4-DIHYDRO-5-METHYL-4-OXO-7-PROPYLIMIDAZO(5,1-F)-AS-TRIAZIN-2-YL)-4-ETHOXYPHENYL)SULFONYL)-4-ETHYLPIPERAZINE

Common Name

English

VIVANZA

Brand Name

English

BAY-389456

Code

English

VARDENAFIL [MI]

Common Name

English

BAY38-9456

Code

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

LEVITRA (AUTHORIZED: ERECTILE DYSFUNCTIONS)

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

NDF-RT

N0000020026

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

FDA ORPHAN DRUG

679319

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

WHO-ATC

G04BE09

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

WHO-VATC

QG04BE09

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

LIVERTOX

NBK548920

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

NCI_THESAURUS

C2127

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

NDF-RT

N0000175599

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

EMA ASSESSMENT REPORTS

VIVANZA (AUTHORIZED: ERECTILE DYSFUNCTIONS)

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

Code System Code Type Description

DAILYMED

UCE6F4125H

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

INN

7950

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

MESH

C426063

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

USAN

NN-53

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

WIKIPEDIA

VARDENAFIL

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

SMS_ID

100000089525

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

NCI_THESAURUS

C66650

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

HSDB

7304

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

IUPHAR

7320

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

LACTMED

Vardenafil

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

RXCUI

306674

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

RxNorm

PUBCHEM

135400189

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

EPA CompTox

DTXSID3048318

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

ChEMBL

CHEMBL1520

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

CAS

224785-90-4

Created by admin on Fri Dec 15 15:44:26 GMT 2023 , Edited by admin on Fri Dec 15 15:44:26 GMT 2023

PRIMARY

DRUG BANK

DB00862

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

FDA UNII

UCE6F4125H

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

DRUG CENTRAL

2809

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

MERCK INDEX

m11394

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

Merck Index

EVMPD

SUB20047

Created by admin on Fri Dec 15 15:44:27 GMT 2023 , Edited by admin on Fri Dec 15 15:44:27 GMT 2023

PRIMARY

Related Record Type Details


					805SU96HKF

CYTOCHROME P450 3A5

METABOLIC ENZYME -> SUBSTRATE


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					5M8S2CU0TS

VARDENAFIL HYDROCHLORIDE

SALT/SOLVATE -> PARENT


					5O8R96XMH7

VARDENAFIL DIHYDROCHLORIDE

SALT/SOLVATE -> PARENT


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MAJOR


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> INHIBITOR

Amount:


					IF61NL91H3

VARDENAFIL HYDROCHLORIDE ANHYDROUS

SALT/SOLVATE -> PARENT

Related Record Type Details


					3DT5R783ZM

BENZENESULFONAMIDE, N-(2-AMINOETHYL)-3-(1,4-DIHYDRO-5-METHYL-4-OXO-7-PROPYLIMIDAZO(5,1-F)(1,2,4)TRIAZIN-2-YL)-4-ETHOXY-

METABOLITE -> PARENT

Qualification:

FECAL; PLASMA


					5W2L2F6HYQ

4-ETHOXY-N-(2-(ETHYLAMINO)ETHYL)-3-(5-METHYL-4-OXO-7-PROPYL-3H-IMIDAZO(5,1-F)(1,2,4)TRIAZIN-2-YL)BENZENESULFONAMIDE

METABOLITE -> PARENT

Comments:

CYP2C9 also contributes to the metabolism of vardenafil.

Interaction Type:

MINOR

Qualification:

FECAL; PLASMA; URINE

Related Record Type Details


					UCE6F4125H

VARDENAFIL

ACTIVE MOIETY

Name	Property Type	Parameters
Tmax	PHARMACOKINETIC	FASTED STATE

Volume of Distribution	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC

Details

SMILES

InChI

DescriptionSources: http://www.drugbank.ca/drugs/DB00862Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021400s017lbl.pdf

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.drugbank.ca/drugs/DB00862
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021400s017lbl.pdf

C_max

T_1/2

Drug as perpetrator